Project title: PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINE

Company name : PROTEA VACCINE TECHNOLOGIES LTD.

TECHNOLOGIES LTD.

TECHNOLOGICAL FIELD
Biotechnology, Vaccine,
Pharmaceuticals

KEY WORDS
Streptococcus Pneumoniae,
Protein-Vaccine, Meningitis, Bacteremia, Otitis

PROJECT SUMMARY
Protea Ltd. is developing a protein based universal vaccine for
Streptococcus pneumoniae.

Streptococcus pneumoniae (Pneumococcus) is a bacterial pathogens
consisting of ~ 90 capsular polysaccharide serotypes that affects
children and adults worldwide. It is the leading cause of illness
in young children and causes illness and death among the elderly
and persons who have certain underlying medical conditions. It is
a leading cause of pneumonia, meningitis, septicemia, otitis and
sinusitis in all ages. Each year in the United States,
Pneumococcal disease accounts for an estimated 3,000 cases of
meningitis, 50,000 cases of bacteremia, 500,000 cases of
pneumonia, and 7 million cases of otitis media. Pneumococcal
infection causes an estimated 40,000 deaths annually in the
United States, accounting for more deaths than any other
vaccine-preventable bacterial disease. Pneumococcus causes an
estimated 800,000 deaths yearly worldwide in children < 5 years
of age. Approximately half of these deaths may potentially be
prevented by vaccination. The global vaccine market is about 6
billions dollars a year, and it is expected to grow over 11
billions in 2010.
The available polysaccharide based vaccines protect against a
narrow but significant group of pneumococcal serotypes, the
vaccinated subjects remaining susceptible to strains not included
in the vaccines. Conjugated polysaccharide vaccines that have
been designed for infants are complex to produce, expensive and
deficient in their spectrum of strain coverage.

Protea aims to develop an efficacious vaccine that will protect
against pneumococcal serotypes prevalent among humans of all ages
in all geographical locations. Using an immunoproteomics-based
approach Protea has identified 38 pneumococcal cell wall
associated proteins that exhibit age dependant immunogenicity in
infants. The proteins were screened for low homology to human
sequences and for sequence conservation among different
pneumococcal strains. Importantly, when administered to mice, the
proteins induce an immune response that protects against
intranasal bacterial challenge. Further studies will delineate
the vaccine `cocktail' comprised of these proteins that induce
optimally protective immune responses. Protea vaccines will not
only protect a wider range of people against a greater number of
strains, but being protein-based, Protea vaccines will be
relative inexpensive to manufacture.

ADVANTAGES
Vaccines expand the coverage of pneumococcal strains active in
infant, elderly people simple to produce and of low cost.

ENTREPRENEURS
Prof. Yaffa Mizrachi Nebenzahl - Founder and CSO, an expert
in pathogen and host immune system interactions
Prof. Ron Dagan - MD, Founder,
Clinical Director, specialist in Pediatric Infectious Diseases
and vaccines
Dr. Michael Tal - CEO

PROJECT STATUS
Protea started to work on June 2006, having a research aim to
discover the optimal vaccination regime with the identified
pneumococcus proteins.
The company has filed Patent applications were filed in USA:
US10/953513 date: 30/9/04, Europa: EP745390.9 date: 09/04,
Canada: 2481107 date: 09/04, Austalia: 203242955 date: 09/04,
Israel: 164242 date: 23/09/04 entitled "Protein-Based
Streptococcus Pneumoniae Vaccine"

COOPERATION REQUIRED
The Company is seeking a partnership with an investor, or a
strategic investor who will provide the funds and expertise to
continue the drug development process.
------------------------------------------------
TEL. 972-54-7929243 E-MAIL: michael@meytavti.co.il

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about